These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 25730350)

  • 21. Impact of metastatic colorectal cancer stage and number of treatment courses on patient health care costs and utilization.
    Chastek B; Kulakodlu M; Valluri S; Seal B
    Postgrad Med; 2013 Mar; 125(2):73-82. PubMed ID: 23816773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer care spending and use by site of provider-administered chemotherapy in Medicare.
    Shooshtari A; Kalidindi Y; Jung J
    Am J Manag Care; 2019 Jun; 25(6):296-300. PubMed ID: 31211557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of time and practice resources required to provide weekly or monthly erythropoiesis-stimulating protein therapy to chronic kidney disease patients in the physician office setting.
    Bernardo M; Crawford P; Hertel J; Sholer C; Xu X; Goss T; Kewalramani R; Globe D
    J Manag Care Pharm; 2006; 12(9):714-25. PubMed ID: 17249904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment patterns among breast cancer patients in the United States using two national surveys on visits to physicians' offices and hospital outpatient departments.
    Wittayanukorn S; Qian J; Westrick SC; Billor N; Johnson B; Hansen RA
    Res Social Adm Pharm; 2015; 11(5):708-20. PubMed ID: 25582892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment patterns, healthcare resource utilization and costs in patients with bipolar disorder, newly treated with extended release or immediate release quetiapine fumarate using US healthcare administrative claims data.
    Locklear JC; Alemayehu B; Brody RS; Chavoshi S; Tunceli O; Kern D; Earley WR
    Clin Ther; 2013 Dec; 35(12):1923-32. PubMed ID: 24275622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost differential by site of service for cancer patients receiving chemotherapy.
    Hayes J; Hoverman RJ; Brow ME; Dilbeck DC; Verrilli DK; Garey J; Espirito JL; Cardona J; Beveridge R
    Am J Manag Care; 2015 Mar; 21(3):e189-96. PubMed ID: 26014306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer.
    Paramore LC; Thomas SK; Knopf KB; Cragin LS; Fraeman KH
    Clin Colorectal Cancer; 2006 May; 6(1):52-8. PubMed ID: 16796792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does site-of-care for oncology infusion therapy influence treatment patterns, cost, and quality in the United States?
    Hopson S; Casebeer A; Stemkowski S; Antol DD; Tao Z; Howe A; Patton J; Small A; Masaquel A
    J Med Econ; 2018 Feb; 21(2):152-162. PubMed ID: 28945163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Healthcare costs in patients with metastatic lung cancer receiving chemotherapy.
    Vera-Llonch M; Weycker D; Glass A; Gao S; Borker R; Barber B; Oster G
    BMC Health Serv Res; 2011 Nov; 11():305. PubMed ID: 22074001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study.
    Hurwitz HI; Bekaii-Saab TS; Bendell JC; Cohn AL; Kozloff M; Roach N; Mun Y; Fish S; Flick ED; Grothey A;
    Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):323-32. PubMed ID: 24686090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bevacizumab in combination with chemotherapy in the first-line treatment of metastatic colorectal carcinoma.
    Usakova V; Sevcikova K; Usak J; Bartosova Z; Mikulova M; Spanik S
    Neoplasma; 2013; 60(1):83-91. PubMed ID: 23067221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting.
    Shah M; Winfree KB; Peterson P; Gruschkus SK; Eaddy M; Green MR
    Lung Cancer; 2013 Oct; 82(1):121-7. PubMed ID: 23973203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis.
    Pelletier EM; Shim B; Goodman S; Amonkar MM
    Breast Cancer Res Treat; 2008 Mar; 108(2):297-305. PubMed ID: 17577662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
    Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
    Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
    Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
    J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patients and Physicians Can Discuss Costs of Cancer Treatment in the Clinic.
    Kelly RJ; Forde PM; Elnahal SM; Forastiere AA; Rosner GL; Smith TJ
    J Oncol Pract; 2015 Jul; 11(4):308-12. PubMed ID: 26015459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.
    Chu E; Schulman KL; McKenna EF; Cartwright T
    Clin Colorectal Cancer; 2010 Oct; 9(4):229-37. PubMed ID: 20920995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer.
    Minion LE; Bai J; Monk BJ; Robin Keller L; Ramez EN; Forde GK; Chan JK; Tewari KS
    Gynecol Oncol; 2015 Jun; 137(3):490-6. PubMed ID: 25766118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 2006 brings new cancer care reimbursement changes to both hospital and office-based settings.
    Downs CG
    ONS News; 2006 Jan; 21(1):11. PubMed ID: 16438090
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.